{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 22,
  "pageCount": 45,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process-flow style layout to define the clinical trial parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/22",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "BCG-Unresponsive NMIBC -> Cretostimogene -> CR at 12-months",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eec68a2a-cd69-4dee-834e-07feae587cc4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "list",
      "text": "Study Design / Regimen: Creto Induction = Weekly x 6; Second induction course = Weekly x 3 or 6; Maintenance courses = Weekly x 3; Pembrolizumab = Every 6 weeks (400 mg) through Year 2",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9365da1-6f8a-44d6-b29c-b44093afa52e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.72,
        "y": 0.45
      },
      "kind": "list",
      "text": "Additional Endpoints: CR at Any Time; DoR; PFS; Safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb61ef32-2539-4bc2-943c-56569855f822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6552cdb-b987-4f41-8b60-844d67ae9416",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders starts at month 3 every 3 months for 1st year, and every 6 months for 2nd year.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c6e110a-db43-423a-831d-736c72ee2da1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Phase 2 Cretostimogene + Pembrolizumab for High-Risk, BCG-Unresponsive NMIBC, CIS-Containing (NCT04387461)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dfe3520-727d-47d8-adc9-a88f032a7eda",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3c641830-5977-42f0-8bd6-882a09727079",
      "evidence": "list/bullet: Population: Pathologically confirmed high-risk NMIBC BCG-unresponsive CIS with or without Ta/T1; Have all Ta/T1 disease resected prior to treatment; Trial designed and compliant with 2018 FDA guidance",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "7899a50d-8cfe-4568-96f5-c92a849ab5c4",
      "evidence": "The slide uses a three-stage horizontal flow to describe the clinical trial structure.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}